Email ID
Password
Scrip   
Sanofi-Aventis pulls out of TroVax but in ocular deal with Oxford BioMedica
01 May 2009
Sita Shah

Sanofi-Aventis has pulled out of developing Oxford BioMedica's novel cancer vaccine TroVax, but will pay the UK company £34 million to develop four preclinical ocular therapies.
Oxford BioMedica regains the worldwide rights to TroVax after its co-development partner Sanofi-Aventis announced this...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36